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dCervical arthroplasty
Results at 24 months from the prospective, randomized, multicenter
Investigational Device Exemption trial of ProDisc-C versus
anterior cervical discectomy and fusion with 4-year follow-up
and continued access patients
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Jeffrey A. Goldstein, MD d, Jack Zigler, MD e, Bobby K-B Tay, MD f,
Bruce Darden II, MD b
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b OrthoCarolina, PA, OrthoCarolina Spine Center, Charlotte, NC
c Center for Spinal Disorders, Thornton, CO
d New York University/Hospital for Joint Diseases, New York, NY
e Texas Back Institute, Plano, TX
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bstract
ackground: Cervical total disk replacement (TDR) is intended to address pain and preserve motion between vertebral bodies in patients
ith symptomatic cervical disk disease. Two-year follow-up for the ProDisc-C (Synthes USA Products, LLC, West Chester, Pennsylvania)
DR clinical trial showed non-inferiority versus anterior cervical discectomy and fusion (ACDF), showing superiority in many clinical
utcomes. We present the 4-year interim follow-up results.
ethods: Patients were randomized (1:1) to ProDisc-C (PDC-R) or ACDF. Patients were assessed preoperatively, and postoperatively at
weeks and 3, 6, 12, 18, 24, 36, and 48 months. After the randomized portion, continued access (CA) patients also underwent ProDisc-C
mplantation, with follow-up visits up to 24 months. Evaluations included Neck Disability Index (NDI), Visual Analog Scale (VAS) for
ain/satisfaction, and radiographic and physical/neurologic examinations.
esults: Randomized patients (103 PDC-R and 106 ACDF) and 136 CA patients were treated at 13 sites. VAS pain and NDI score improvements
rom baseline were significant for all patients (P  .0001) but did not differ among groups. VAS satisfaction was higher at all time points for
DC-R versus ACDF patients (P .0499 at 48 months). The percentage of patients who responded yes to surgery again was 85.6% at 24 months
nd 88.9% at 48 months in the PDC-R group, 80.9% at 24 months and 81.0% at 48 months in the ACDF group, and 86.3% at 24 months in the
A group. Five PDC-R patients (48 months) and no CA patients (24 months) had index-level bridging bone. By 48 months, approximately 4-fold
ore ACDF patients required secondary surgery (3 of 103 PDC-R patients [2.9%] vs 12 of 106 ACDF patients [11.3%], P  .0292). Of these,
ACDF patients (5.6%) required procedures at adjacent levels. Three CA patients required secondary procedures (24 months).
onclusions: Our 4-year data support that ProDisc-C TDR and ACDF are viable surgical options for symptomatic cervical disk disease.
lthough ACDF patients may be at higher risk for additional surgical intervention, patients in both groups show good clinical results at
onger-term follow-up.
2010 SAS - The International Society for the Advancement of Spine Surgery. Published by Elsevier Inc. All rights reserved.
eywords: Cervical arthroplasty; Symptomatic cervical disc disease; Total disc replacement
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tSince 2007, 3 cervical total disk replacement (TDR)
rostheses have been approved by the Food and Drug Ad-
inistration (FDA) for marketing in the United States. As
* Corresponding author: Rick B. Delamarter, MD, The Spine Institute at
aint John’s Health Center, 1301 20th St, Ste 400, Santa Monica, CA
0404; Tel.: 310-828-7757; Fax: 310-828-6847.mE-mail address: rdelamar@msn.com
935-9810 © 2010 SAS - The International Society for the Advancement of Spin
oi:10.1016/j.esas.2010.09.001art of their application to the FDA, these devices under-
ent an Investigational Device Exemption clinical trial and
-year follow-up results were presented.1–3 All 3 studies
howed non-inferiority of the investigational device com-
ared with anterior cervical discectomy and fusion (ACDF).
he ProDisc-C (Synthes USA Products, LLC, West Ches-
er, Pennsylvania) TDR was also able to prove superiority in
any clinical outcomes in comparison to ACDF.1 However,
e Surgery. Published by Elsevier Inc. All rights reserved.
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123R.B. Delamarter et al. / SAS Journal 4 (2010) 122–128here was still a significant concern in the medical commu-
ity regarding performance over the longer term and
hether these areas of superiority compared with ACDF
ould bear out over time.
Widely accepted as one of the most successful spine
rocedures performed today, ACDF was first described by
mith and Robinson4 in 1958 and remained largely un-
hanged until the 1990s, when anterior cervical plates were
ntroduced. However, there has been increased reporting of
djacent segment degeneration ranging from 2.9% to 6.9%
er year as a consequence of ACDF5–10 despite reports of
igh fusion rates.5,11–13 It has been shown in biomechanical
n vitro studies that fusion causes increased stress or motion
t the adjacent levels,14–16 and it has been hypothesized that
his may contribute to adjacent segment breakdown by
hanging segmental motion and increasing strains in the
ntervertebral disk adjacent to fusion.16 Long-term data will
how whether substituting arthroplasty for fusion will re-
uce the incidence of adjacent segment degeneration.
The purpose of this report is to present the 4-year fol-
ow-up results of the ProDisc-C TDR clinical trial.
aterials and methods
Complete methodology of this prospective, randomized,
ontrolled, multicenter trial was previously described by
urrey et al.1 In brief, patients with symptomatic cervical
isk disease who were unresponsive to nonoperative treat-
ents for at least 6 weeks, met the inclusion/exclusion criteria,
nd had signed informed consent forms were randomized in a
:1 ratio to ProDisc-C (PDC-R) or ACDF. Patients remained
linded to randomization until immediately after surgery. After
nrollment of the randomized portion of the clinical trial was
ompleted, the FDA allowed the study investigators to con-
inue to implant the investigational device in patients who met
he original study criteria until study approval. These patients
ere termed continued access (CA).
Patients were evaluated preoperatively and postopera-
ively at 6 weeks and 3, 6, 12, 18, 24, 36, and 48 months.
A patients had only reached the 24-month follow-up time
oint at the time of this report. Patient self-assessments
ncluded Neck Disability Index (NDI) questionnaire, Short
orm 36 (SF-36), neck and arm pain intensity on a 100-mm
isual analog scale (VAS), and VAS for patient satisfaction.
hysical and neurologic examinations included root tension,
eflexes, muscle strength, and sensory deficits. Radio-
raphic evaluation consisted of anteroposterior and lateral
tanding, flexion, and extension films. Radiographic analy-
is of range of motion (ROM) was measured by an inde-
endent third party (Medical Metrics Inc., Houston, Texas).
For between–treatment group comparisons of continuous
easurements such as NDI, VAS for pain, and SF-36
cores, the Wilcoxon rank sum test was used. To compare
he mean improvement from baseline within the treatment
roups for the patient self-assessment data at each follow-up
isit, paired t tests were performed. The Fisher’s exact test aas used to compare success rates between treatment
roups such as neurologic success and the percentage of
atients indicating that they would have the surgery again.
esults
From August 2003 to October 2004, 209 randomized
atients (103 PDC-R and 106 ACDF) had surgery at 13
nvestigational sites across the United States and are con-
inuing to be followed up for 7 years. After closure of
andomized enrollment in 2004, an additional series of 136
A patients had ProDisc-C TDR surgery from March 2005
o January 2008. Follow-up rates at 24 months were 98.0%
or PDC-R, 94.8% for ACDF, and 77.4% for CA. At the
ime of this publication, the follow-up rates for PDC-R and
CDF were 63.0% and 46.2%, respectively, at 48 months.
verall patient demographics showed no difference be-
ween randomized and CA cohorts of ProDisc-C–treated or
CDF-treated patients (Table 1). Operative time (PDC-R,
07.4 minutes; ACDF, 98.7 minutes; and CA, 108.8 min-
tes) and estimated blood loss (PDC-R, 83.5 mL; ACDF,
3.5 mL; and CA, 84.2 mL) were statistically lower for
CDF compared with PDC-R patients (P  .0063 and P 
0094, respectively). There was no difference between
DC-R or ACDF patients and CA patients in operative time
r blood loss.
eurologic success
Neurologic success was defined as maintenance or im-
rovement in each of the neurologic evaluations including
ensory, motor, and reflex functions. At 24 months, the
eurologic success rate was not different among the 3
roups (PDC-R, 90.9%; ACDF, 88.0%; and CA, 94.3%).
oth the PDC-R and ACDF groups were able to maintain
eurologic success levels from 24 to 48 months, because 24-
nd 48-month follow-up values were not statistically different.
t 48 months, the overall neurologic success rate trended
oward significance for PDC-R patients (88.9%) compared
ith ACDF patients (74.4%) (P  .0665).
eck Disability Index
Preoperative NDI scores were not different between
roups (PDC-R, 53.9  15.1; ACDF, 52.2  14.5; and CA,
2.1  12.7). Regardless of treatment, all patients showed
tatistically significant improvement in NDI scores at all
ollow-up periods compared with baseline (P  .0001)
Fig. 1). At 24 months, there was no significant difference
een between groups. The mean NDI score was 21.4 20.3
or PDC-R patients, 20.6  18.4 for ACDF patients, and
8.5  17.7 for CA patients. These scores represent a 60.3%,
0.6%, and 64.5% improvement from baseline, respectively.
t 48 months, the mean NDI score was 20.3  18.6 for
DC-R patients and 21.2  14.9 for ACDF patients, a 62.3%
nd 59.5% improvement from baseline, respectively.
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VAS neck and arm pain intensity assessments indicated
tatistically significant improvement from preoperative scores
egardless of treatment (P  .0001) (Figs. 2 and 3). At 24
onths, mean VAS neck pain intensity scores were reduced by
7.3 mm in the PDC-R group, 41.5 mm in the ACDF group,
nd 49.8 mm in the CA group. At 48 months, the ACDF group
howed only a 38.7 mm reduction in mean VAS score from
reoperative levels compared with 49.3 mm in the PDC-R
roup, although this difference was not statistically significant.
t 24 months, a reduction of 43.7 mm was observed in mean
AS arm pain intensity scores in the PDC-R group, 43.4 mm
n the ACDF group, and 43.8 mm in the CA group. At 48
onths, the PDC-R group maintained a 43.8-mm reduction in
ean VAS score, whereas ACDF patients showed a 40.2-mm
eduction in mean VAS score compared with preoperative
core.
hort Form 36
Regardless of treatment and at all time points, there was
statistically significant improvement in SF-36 scores from
able 1
atient demographics and intraoperative data.
ariable
ACDF
(n  106)
Pro
(n
atient demographics
Gender [n (%)]
Male 57 (53.8%)
Female 49 (46.2%)
Age (years)
n 106 10
Mean (SD) 43.5 (7.2) 4
Race [n (%)]
White 88 (85.4%)
African American 4 (3.9%)
Hispanic 3 (2.9%)
Asian 5 (4.9%)
Other 3 (2.9%)
Body mass index
n 106 10
Mean (SD) (kg/m2) 27.3 (5.5) 2
Smoking status
Former 20 (22.5%)
Current 37 (34.9%)
ntraoperative data
Implant level
C3–C4 1 (0.09%)
C4–C5 6 (5.7%)
C5–C6 61 (57.5%)
C6–C7 38 (35.8%)
Intraoperative time
n 106 10
Mean (SD) (minutes) 98.7 (47.0) 10
Estimated blood loss
n 105 10
Mean (SD) (mL) 63.5 (50.4) 8
D  standard deviation.
* Continuous variables were analyzed by the Wilcoxon rank sum test; cateaseline (P  .0016). At 24 months, SF-36 physical com- aonent scores improved in 83.8% of PDC-R patients, 84.4%
f ACDF patients, and 84.6% of CA patients. At 48 months,
7.1% of PDC-R patients and 83.3% of ACDF patients
howed improvement. At 24 months, SF-36 mental compo-
ent scores improved in 75.8% of PDC-R patients, 80.0% of
CDF patients, and 76.0% of CA patients. At 48 months,
mprovement was seen in 80.6% of patients in the PDC-R
roup whereas only 73.8% of ACDF patients showed im-
rovement.
atient satisfaction and surgery again
VAS patient satisfaction (Fig. 4) was higher at all time
oints for PDC-R patients compared with the ACDF group. At
4 months, the mean satisfaction score was 83.4  24.8 mm
or PDC-R patients, 80.0  28.0 mm for ACDF patients, and
7.3  20.0 mm for CA patients. At 48 months, there was a
tatistically significant difference in the mean satisfaction score
n PDC-R patients (85.5  23.7 mm) compared with ACDF
atients (76.4  30.6 mm) (P  .0499). The percentage of
atients considered very to completely satisfied (60–100 mm)
as 86.3% in the PDC-R group, 83.0% in the ACDF group,
(PDC-R): ProDisc-C (CA):
(n  136)
P value* for
PDC-R vs ACDF
.89
3%) 58 (42.7%)
7%) 78 (57.4%)
.20
134
) 43.5 (8.0)
.10
5%) 125 (92.6%)
%) 0 (0%)
%) 1 (0.7%)
) 5 (3.7%)
%) 4 (3.0%)
.09
135
) 26.7 (5.1)
.88
0%) 30 (24.2%)
0%) 27 (19.9%)
%) 4 (2.9%) .48
%) 14 (10.3%)
3%) 82 (60.3%)
1%) 36 (26.5%)
.0063
135
6) 108.8 (48.6)
.009
135
9) 84.2 (84.6)
ariables were analyzed using Fisher’s exact test.Disc-C
 103)
57 (55.
46 (44.
3
2.1 (8.4
97 (91.
1 (0.9
5 (4.7
0 (0%
3 (2.8
3
6.4 (5.3
18 (20.
34 (33.
3 (2.9
10 (9.7
58 (56.
32 (31.
3
7.4 (35.
3
3.5 (64.nd 90.5% in the CA group. At 48 months, the percentage of
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125R.B. Delamarter et al. / SAS Journal 4 (2010) 122–128atients considered very to completely satisfied (60–100 mm)
tayed consistent for PDC-R patients (85.7%) while dropping
n the ACDF group (76.2%).
Patients were asked whether they would have the same
urgical treatment again. At 24 months, 85.6% of PDC-R
atients, 80.9% of ACDF patients, and 86.3% of CA pa-
ients responded yes, they would have the same surgery
ig. 1. Mean Neck Disability Index (NDI) scores for anterior cervical di
ontinued access (CA) patients over time. CA patients were followed out
ig. 2. Mean Visual Analog Scale (VAS) neck pain intensity scores for an
nd ProDisc-C continued access (CA) patients over time. CA patients were follogain. At 48 months, 88.9% of PDC-R and 81.0% of ACDF
atients responded yes.
adiography
At 24 months, flexion-extension ROM at the index level
veraged 9.38° 5.97° for PDC-R patients and 9.50° 5.15°
y and fusion (ACDF), ProDisc-C randomized (PDC-R), and ProDisc-C
onths. Error bars represent standard deviation.
ervical discectomy and fusion (ACDF), ProDisc-C randomized (PDC-R),scectomterior c
wed out to 24 months. Error bars represent standard deviation.
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126 R.B. Delamarter et al. / SAS Journal 4 (2010) 122–128or CA patients. At 48 months, flexion-extension ROM was
aintained in PDC-R patients (9.12° 6.06°). By 24 months,
cases of bridging bone were identified at the index level in
he PDC-R group. Between 24 and 48 months, an additional 2
ases of bridging bone were identified in the PDC-R group. No
ig. 3. Mean Visual Analog Scale (VAS) arm pain intensity scores for an
nd ProDisc-C continued access (CA) patients over time. CA patients we
ig. 4. Mean Visual Analog Scale (VAS) patient satisfaction scores for an
nd ProDisc-C continued access (CA) patients over time. CA patients were folloases of bridging bone were observed in the CA group at up to
4 months.
At 24 months, 91.2% of the ACDF patients had 2°
OM; by 48 months, 95.5% of the ACDF group had 2°
OM.
ervical discectomy and fusion (ACDF), ProDisc-C randomized (PDC-R),
wed out to 24 months. Error bars represent standard deviation.
ervical discectomy and fusion (ACDF), ProDisc-C randomized (PDC-R),terior cterior c
wed out to 24 months. Error bars represent standard deviation.
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127R.B. Delamarter et al. / SAS Journal 4 (2010) 122–128econdary surgical procedures
Secondary surgical procedures were defined as any re-
peration, revision, supplemental fixation, or removal of the
mplant. By 24 months, of the patients originally enrolled in
he study, 2 (1.9%) in the PDC-R group and 9 (8.5%) in the
CDF group required a secondary surgical procedure. From
4 to 48 months, 1 additional PDC-R patient and 3 addi-
ional ACDF patients required secondary surgery. By 48
onths, 2.9% of PDC-R patients and 11.3% of ACDF
atients had required a secondary surgical procedure—an
pproximately 4-fold difference (P  .0292).
The 3 PDC-R patients reported ongoing pain and were
onverted to fusion. One patient reported worsening pain; the
DR was removed and the level converted to a fusion. The
econd case involved removal of the TDR and revision to a
-level ACDF because of return of nonspecific neck pain. The
hird patient underwent a posterior decompression with sup-
lemental fixation at C6-T1; the TDR was left intact.
Of the 12 secondary surgeries that occurred in the ACDF
roup, 6 included an adjacent level in addition to the index
evel. The primary reason for revision at the index level was
seudarthrosis; 1 patient underwent revision because of
ysphagia associated with plate liftoff, and 1 patient under-
ent posterior decompression for foraminal stenosis. Of the
patients (5.6%) who required procedures at the adjacent
evel, an ACDF was performed at 1 adjacent level in 3
atients and at both adjacent levels in 3 patients.
In the CA group, 3 patients required a secondary surgical
rocedure by the 24-month follow-up time point. In 1 case
he implant was repositioned 4 days after surgery. Increas-
ng radiculopathy developed in 1 patient due to hypermo-
ility at the index level, and this patient underwent revision
o anterior fusion. One patient reported increasing trapezial
nd arm pain; the implant was removed, and the index and
djacent levels were converted to anterior fusion.
iscussion
Although a hypothesized benefit of TDR surgery is the
eduction of adjacent segment disease alone, this prospective
tudy shows a reduction in the overall rate of secondary sur-
ical interventions at both the index and adjacent levels. A
-fold increase in reoperation rates at the index and adjacent
evels for ACDF-treated patients compared with PDC-R–
reated patients was shown in these longer-term results. The
eoperations in the ACDF group were mainly for pseudarthro-
is at the index level or the development of symptomatic
egeneration at an adjacent level. By 48 months, 5.6% of
CDF patients required further surgery at an adjacent level.
his rate was higher than the 1.9% rate observed in the PDC-R
roup. Though preliminary, these results indicate that TDR
oes slow the rate of adjacent-level disease.
The rate of reoperation for symptomatic adjacent seg-
ent disease after cervical fusion was 1.4% per year in thistudy, slightly lower than the 1.5% to 4% rate reported inhe literature.7 However, it must be noted that the patients
nrolled in this study were limited to single-level disease,
hereas the large patient series reported by Hilibrand et al6
nd Goffin et al17 include a substantial number of multilevel
rocedures. Many clinical series have established that pa-
ients with multilevel cervical fusions have a higher inci-
ence of adjacent-level disease progression when compared
ith single-level fusions.
In the PDC-R group, radiographic evaluation showed 5
ases of bridging bone. Three of these cases were observed
t 12 to 18 months follow-up and two were noted at the
8-month follow-up. This radiographic finding was asymp-
omatic in these 5 patients. Extensive analysis has shown
hat in none of these cases was there any correlation be-
ween the development of bridging bone and an effect on
linical outcomes compared with the remainder of the
DC-R group. There were no cases of bridging bone re-
orted in the CA group. This difference is likely because of
reater attention to soft-tissue handling, endplate prepara-
ion, controlling bleeding, and use of bone wax. Nonsteroi-
al anti-inflammatory drugs were not required in this study,
nd most investigators did not administer them.
With any new technology, there are always the questions of
ow steep the learning curve is and how experience affects
atient outcomes. In this study the clinical outcomes of the
andomized and CA ProDisc-C patients observed up to 24
onths were comparable. Given the relatively straightforward
urgical technique, it appears that a learning curve does not
lay a factor and patient outcomes are not affected.
This report is limited by the lower patient accountability
t 48 months compared with 24 months. This is a continuing
tudy, and follow-up is ongoing. Nevertheless, these pre-
iminary data at 4 years show that both TDR and ACDF are
iable surgical options for patients with symptomatic cer-
ical disk disease. Although it appears that ACDF patients
re at higher risk for having an additional surgical interven-
ion at the index level or an adjacent level, patients in both
roups continue to show good clinical results at longer-term
ollow-up.
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